Dewpoint doubles up on major milestones with oral small-molecule condensate modulator

US biotech Dewpoint Therapeutics has announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to DPTX3186, its first-in-class condensate modulator for the treatment of gastric cancer.

The designation follows the recent opening of Dewpoint’s Investigational New Drug (IND) application for DPTX3186, marking the company’s transition to a clinical-stage biotech and the first human study of a condensate-modulating therapeutic.

'An extraordinary validation'

Isaac Klein, chief scientific officer and head of R&D at the Boston firm, said: “The FDA’s decision to grant Orphan Drug Designation to DPTX3186 is an extraordinary validation of both the promise of condensate biology and the importance of our work in gastric cancer.

“This recognition reflects the agency’s confidence in our mechanism, our science, and our shared goal of bringing new hope to patients facing this devastating disease.”

DPTX3186 is an oral small-molecule condensate modulator designed to selectively target oncogenic Wnt/β-catenin signaling by redistributing β-catenin into an inactive condensate state within tumor cells—a mechanism that overcomes historical safety challenges associated with Wnt inhibition. The program is accompanied by a condensate-based biomarker strategy that directly measures pharmacodynamic effects in patient samples.

Dewpoint expects to dose the first patient with DPTX3186 before year-end 2025 at leading cancer centers in the USA.

The Orphan Drug Designation program is designed to encourage the development of medicines for rare diseases or conditions affecting fewer than 200,000 people in the USA. 

Receipt of this designation provides several important advantages, including seven years of market exclusivity upon approval, FDA fee waivers, tax credits for qualified clinical trials and eligibility for enhanced regulatory support and expedited review.

IND opening a huge milestone

The opening of the IND for DPTX3186 was announced last week, with Dewpoint revealing plans to begin dosing its first patient before the end of 2025 in a combined Phase I/II trial conducted in partnership with leading cancer centers and key opinion leaders in gastric and other Wnt-driven cancers.

It marked a significant milestone in Dewpoint’s journey and underscores the strength of its partnership with Evotec (ETR: EVT), a Germany-based drug discovery and development company.

Evotec employed its deep expertise in drug development to provide integrated support across preclinical, regulatory, and CMC, helping to translate a de novo candidate emerging from Dewpoint’s proprietary c-mod platform into a robust and clinically ready investigational therapy.

Ameet Nathwani, chief executive of Dewpoint, said: “Evotec’s depth of experience and proven track record in advancing first-in-class small molecules through their Evotec INDiGO platform made them an ideal partner for this effort.

“Their scientific rigor and development agility were instrumental in helping us take a novel condensate-derived mechanism from concept to IND. For a young biotech company like Dewpoint moving into the clinic for the first time, working alongside a partner of Evotec’s caliber significantly de-risked and accelerated our path to the clinic.”

DPTX3186 was discovered and optimized using Dewpoint’s proprietary condensate-modulating drug discovery platform. The unique forcing of β-catenin to concentrate within an inactive condensate inside tumor cells represents a novel spatial sequestration mechanism that overcomes historic toxicity hurdles that have plagued previous Wnt-targeting approaches. 

'Defining moment'

Dr Klein added: “Dosing our first patient this year will be a defining moment for condensate biology and Dewpoint.

“DPTX3186 is the only molecule of its kind: an oral small-molecule c-mod tackling a historically undruggable pathway with a differentiated safety profile. Its discovery on our platform, the bespoke biomarker strategy, and the caliber of partners supporting this trial reflect the transformative potential of condensate science to rewrite what is possible in drug discovery and development.”

Cord Dohrmann, chief scientific officer of Evotec, added: “Evotec is proud to support Dewpoint in translating an entirely new modality from biology to clinic. The DPTX3186 program exemplifies how next-generation science and disciplined execution must go hand in hand. 

“Dewpoint’s advanced expertise in condensate biology and Evotec’s integrated development platform capabilities have together enabled a smoother, more de-risked path to IND. This project reflects the kind of collaborative, high-science partnerships that will define the future of innovative drug development.”

The initial study will evaluate the safety, pharmacokinetics, and preliminary efficacy of DPTX3186 as a single agent, with a focus on metastatic gastric cancer. Planned expansion cohorts will include combination regimens and additional tumor types. 

Meanwhile, Dewpoint’s strategic collaborations with Bayer (BAYN: DE), Novo Nordisk (NOVN: VX), and Mitsubishi Tanabe Pharma, alongside its AI/ML-enabled discovery platform, continue to fuel a pipeline spanning oncology, neurodegenerative, cardiopulmonary, and metabolic diseases.